(MedPage Today) — A patient with transthyretin amyloidosis (ATTR) who received the investigational gene therapy nexiguran ziclumeran (nex-z) in a phase III trial died, Intellia Therapeutics said.
The news came days after the company paused the…
Source link : https://www.medpagetoday.com/cardiology/generalcardiology/118385
Author :
Publish date : 2025-11-07 22:28:00
Copyright for syndicated content belongs to the linked Source.
